| Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction RC Hillig, B Sautier, J Schroeder, D Moosmayer, A Hilpmann, ... Proceedings of the National Academy of Sciences 116 (7), 2551-2560, 2019 | 323 | 2019 |
| Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis A Santamaria, R Neef, U Eberspächer, K Eis, M Husemann, D Mumberg, ... Molecular biology of the cell 18 (10), 4024-4036, 2007 | 233 | 2007 |
| Recovery of Carbonyl Compounds from N,N-Dialkylhydrazones D Enders, L Wortmann, R Peters Accounts of chemical research 33 (3), 157-169, 2000 | 167 | 2000 |
| The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage–inducing or repair–compromising therapies in preclinical cancer models AM Wengner, G Siemeister, U Lücking, J Lefranc, L Wortmann, P Lienau, ... Molecular cancer therapeutics 19 (1), 26-38, 2020 | 152 | 2020 |
| Prey for the proteasome: targeted protein degradation—a medicinal chemist's perspective LM Luh, U Scheib, K Juenemann, L Wortmann, M Brands, PM Cromm Angewandte Chemie International Edition 59 (36), 15448-15466, 2020 | 110 | 2020 |
| Localized inhibition of protein phosphatase 1 by NUAK1 promotes spliceosome activity and reveals a MYC-sensitive feedback control of transcription G Cossa, I Roeschert, F Prinz, A Baluapuri, RS Vidal, C Schülein-Völk, ... Molecular cell 77 (6), 1322-1339. e11, 2020 | 52 | 2020 |
| Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in … U Lücking, L Wortmann, AM Wengner, J Lefranc, P Lienau, H Briem, ... Journal of medicinal chemistry 63 (13), 7293-7325, 2020 | 43 | 2020 |
| Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2-d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5 D Nguyen, C Lemos, L Wortmann, K Eis, SJ Holton, U Boemer, ... Journal of medicinal chemistry 62 (2), 928-940, 2018 | 39 | 2018 |
| Chk-, Pdk-and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents J Bryant, MJ Kochanny, S Yuan, SK Khim, BO Buckman, DO Arnaiz, ... US Patent 7,504,410, 2009 | 29 | 2009 |
| Acyltryptophanols L Wortmann, A Cleve, B Menzenbach, HP Muhn, G Langer, A Schrey, ... US Patent App. 11/501,228, 2007 | 29 | 2007 |
| Latest advances towards ras inhibition: A medicinal chemistry perspective B Sautier, CF Nising, L Wortmann Angewandte Chemie International Edition 55 (52), 15982-15988, 2016 | 28 | 2016 |
| Novel and Efficient Copper‐Catalysed Synthesis of Nitrogen‐Linked Medium‐Ring Biaryls JL Kenwright, WRJD Galloway, DT Blackwell, A Isidro‐Llobet, ... Chemistry–A European Journal 17 (10), 2981-2986, 2011 | 26 | 2011 |
| Late-stage sulfoximidation of electron-rich arenes by photoredox catalysis H Lämmermann, A Sudau, D Rackl, H Weinmann, K Collins, L Wortmann, ... Synlett 29 (20), 2679-2684, 2018 | 24 | 2018 |
| Mild and efficient synthesis of benzo-fused seven-and eight-membered ring lactams: A convenient approach to biologically interesting chemotypes JL Kenwright, WRJD Galloway, L Wortmann, DR Spring Synthetic Communications 43 (11), 1508-1516, 2013 | 23 | 2013 |
| 2-(morpholin-4-yl)-1, 7-naphthyridines L Wortmann, U Lücking, J Lefranc, H Briem, F Von Nussbaum, B Bader, ... US Patent 9,549,932, 2017 | 21 | 2017 |
| Discovery of BAY-298 and BAY-899: tetrahydro-1, 6-naphthyridine-based, potent, and selective antagonists of the luteinizing hormone receptor which reduce sex hormone levels in vivo L Wortmann, B Lindenthal, P Muhn, A Walter, R Nubbemeyer, ... Journal of Medicinal Chemistry 62 (22), 10321-10341, 2019 | 17 | 2019 |
| Asymmetric Synthesis of 1, 2, 3, 4, 5, 6‐Hexahydro‐5‐hydroxypyrimidin‐2‐ones as Potential HIV‐Protease Inhibitors D Enders, L Wortmann, B Dücker, G Raabe Helvetica chimica acta 82 (8), 1195-1201, 1999 | 16 | 1999 |
| Discovery and characterization of the potent and highly selective 1, 7-naphthyridine-based inhibitors BAY-091 and BAY-297 of the kinase PIP4K2A L Wortmann, N Bräuer, SJ Holton, H Irlbacher, J Weiske, C Lechner, ... Journal of Medicinal Chemistry 64 (21), 15883-15911, 2021 | 15 | 2021 |
| Thiazolidinones, their production and use as pharmaceutical agents V Schulze, K Eis, L Wortmann, D Kosemund, O Prien, G Siemeister, ... US Patent 7,511,059, 2009 | 15 | 2009 |
| Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in … UT Luecking, J Lefranc, A Wengner, L Wortmann, H Schick, H Briem, ... Cancer Research 77 (13_Supplement), 983-983, 2017 | 13 | 2017 |
Franz von NussbaumBayerVerified email at bayer.com
